IMUGENE LIMITED — AGM Information 2008

Nov 27, 2008

==> picture [128 x 47] intentionally omitted <==

ASX RELEASE

28 November 2008

Company Announcements Platform Australian Stock Exchange Level 4 20 Bridge Street SYDNEY NSW 2000

By e-Lodgement

Dear Sir/Madam

AGM PRESENTATION

Please find attached a copy of the presentation given to shareholders at the 2008 Annual General Meeting of Imugene Limited (ASX: IMU) this morning in Sydney.

Yours faithfully IMUGENE LIMITED

Julie Foster Company Secretary

Perth Office

Level 20, Allendale Square 77 St Georges Terrace Perth WA 6000 Tel: +61 8 9440 2660 Fax: +61 8 9440 2699

ABN: 99 009 179 551

www.imugene.com

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

==> picture [720 x 47] intentionally omitted <==

IMUGENE LIMITED Advanced Vaccine Technologies Disease control in pigs and poultry Annual General Meeting 28 November 2008

Dr Warwick Lamb Managing Director

==> picture [125 x 47] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Developer of Pig & Poultry vaccines

• Platform adenoviral vector delivery of desired antigens or cytokines

• Fowl Adenovirus & Porcine Adenovirus

• Patents granted in major regions (US & Europe)

• 5 vaccines through proof of concept

• 3 vaccines currently in animal trials

• 3 additional vaccines ready for animal trials

• Development strategy on track

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• An early stage developer of adenoviral vaccines

• • Spent 3 years improving science & patents

• • Has completed several proof of concept trials, mostly in the US

• Laboratory at La Trobe Uni – Melbourne, Australia

• Products for large markets

• poultry – 50 billion birds produced pa

• – i 1 billi i

• p gs – on p gs pa

• Value of markets >U$4 billion

• individual vaccines sales target >U$100m

==> picture [125 x 47] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Proof of concept achieved for two big animal health disease targets

• Coccidiosis vaccine for broiler chickens

• PRRS vaccine for pigs

• POC achieved in animal trials – high dose of disease used to ‘challenge’ animals

• P d rogresse

• US Regulatory processes

– Commercial Development Strategy

• Patents – progress in expanding coverage

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

Proof of Concept – achieved

– Poultry

• Coccidiosis

• Avian Influenza – H5N1

• Gamma Interferon – immune & growth enhancer

• Pigs

• Porcine Reproductive and Respiratory Syndrome

• Classical Swine Fever

==> picture [721 x 136] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

Proof of Concept – required

• Poultry

• Infectious Bursal Disease

  • Classical strain

  • Very virulent Strain

• Chicken Anemia Virus

• Avian Influenza - H7 and H9

• Pigs

• Porcine Circovirus

• Cytokine based immune system & growth enhancer

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Flexible Administration – cost effective

• water, aerosol, in ovo, injection

• Inexpensive to manufacture

• Delivers key genetic information

• Does not cause disease

• Ubiquitous in poultry and swine

• Safe - no residue

• Limited or no shedding

• • No genetic modification o an mat i l

• Marker vaccine (DIVA)

• • Platform delivery system for large product portfolio

==> picture [125 x 47] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• PAV patent family

• Granted in US, Europe, China, Australia & others

• Initial patents expiry 2018

• Successfully underwent Interference in the US – claims interfered with VIDO & Uni of Saskatchawan – resulted in Imugene receiving assignment of patents

• FAV patent family

• Granted in US, Europe, Australia & others

• Initial patents expiry 2014

• Additional FAV and PAV patents recently filed to extend product life

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Coccidiosis – Broiler vaccine

Initial Trial results – ABIC/University of Technology, Sydney

• Blinded trial 24 groups of 20 broilers per group

• Successful groups had 2 oral doses (day 1 and 14)

• Emeria maxima challenge on day 28

• The best performing vaccine group’s results are: Lesion scoring:

74% of birds had a score of 1 lesion (control group 6%) 11% of birds had a score of 3 lesions or more (control group 44%) Oocyst scoring:

Group max daily oocyst count <68,000 (control >350,000) – reduction 80% Group total oocyst count <139,000 (control group >668,000) – reduction 79%

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• 3 groups, 15 piglets (21 day old)

==> picture [721 x 339] intentionally omitted <==

----- Start of picture text -----

Virus Isolation from sera in control and vaccinated pigs
(challenge on Day 28)
80%
70%
60%
50%
T1
40% T2
T3
30%
20%
10%
0%
Day 28 Day 32 Day 35 Day 38 Day 42
----- End of picture text -----

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

Average Lung Scores

==> picture [721 x 361] intentionally omitted <==

----- Start of picture text -----

10
8
6
Control
IM
4
Oral
2
0
Day 42
ge
ogy
a l
Percent g Patho
verage otal Lu n
A T
----- End of picture text -----

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

PRRS Virus Isolation from Pig Lungs

==> picture [721 x 343] intentionally omitted <==

----- Start of picture text -----

80
70
60
50
Control
40
IM
30
Oral
20
10
0
Day 42
ion
sitive for t
Pigs Po us Isola r
ntage of RRS Vi
e P
Perc
----- End of picture text -----

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

Percentage of PRRS Antibody Positive Pigs

==> picture [721 x 377] intentionally omitted <==

----- Start of picture text -----

100
90
80
70
60
50
40 Control
30
IM
20
Oral
10
0
Day of PRRSV challenge
age
t
Percen
08 08 08 08 08
8/7/20
3/07/20 17/07/20 31/07/20 14/08/20
----- End of picture text -----*

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Broiler Productivity Enhancer (gamma interferon)

– Significant Trial results - rFAdV-CMV-IFNg vaccine

• Double Blinded 900 broiler trial (group size 50 birds):

• Feed conversion improved by up to

  • 11 . 7% compared to Ross Index & 9 . 2% compared to medicated control group

• Weight gains improved by up to

  • 15.6% compared to Ross Index & 13.75% compared to medicated control group

• Effective with or without antibiotics in feed

• 18 groups – doses ranged from 2 dose to 4 dose – Day 0 to day 28

• Dosage & stability – required

• Manufacturing – production technique required (cell line,

eggs)

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Proof of concept H5N1 – in ovo & oral – passed in 2007

• Additional suite – H7 & H9 – constructs available for trial

• Diagnostic – matched to each vaccine

• H5N1 trial results

• Conducted by Benchmark in the US

• 2 dose group (in ovo & oral at day 7) challenge at day 21

  • 100% survival (8 birds) control group 12.5% survival (1 out of 8 birds)

• 1 dose group (in ovo) challenge at day 14

  • 82 % survival (9 out of 11 birds) control group 37.5% survival (3 out of 8 birds)

• Platform suitable to make vaccines against other avian influenza viruses

• Heterologous challenge model (challenge – Asian Strain)

• Dosage, stability & manufacturing – required

==> picture [125 x 47] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

----- Start of picture text -----

Infectious Bursal Disease
----- End of picture text -----

– Recombinants made for 2 strains

• Class cai l

• Very virulent

• Freedom to operate with VP2 genes

– Vaccine candidates ready for trialling – Proof of concept designed and approved – Classical version - POC trials underway

• Proof of concept designed and approved

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

– Recombinant constructed and verified in lab

• Vaccine candidates ready for trialling

• Freedom to operate

– Proof of concept trial designed and approved – POC trials underway

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

----- Start of picture text -----

-
Porcine Circovirus PCV
----- End of picture text -----

==> picture [720 x 69] intentionally omitted <==

• Recombinant constructed

• Laboratory verified

• Ready to proceed to trials

• • First POC trial planned in US to complete 1[st] qtr 2009

==> picture [721 x 204] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Directors & management

  • Graham Dowland – Chairman

  • Warwick Lamb – CEO

  • Roger Steinepreis – Director

  • Mike Sheppard – Chief Scientific Officer

• Shares on issue

• Options – Dec 09, 25c

143 6 m. 4.3 m

• Options – Mar 11, 20c

3.0 m

• Ownership:

• Board, management & their associates

14 %

• No debt, Minimal overhead, Cash 30 Sep 08 $1.4 m

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Focus on proven products

• Alliances with International Industry

• US & Europe

• • Continue regu al tory processes

• Lab will focus on existing range

• Complete trials on range extension products

• By 1[st] qtr 2009

• Commence evaluation of contract manufacturing for vaccine range

==> picture [721 x 69] intentionally omitted <==

==> picture [720 x 68] intentionally omitted <==

==> picture [720 x 69] intentionally omitted <==

• Products meet demand in large global markets

• Large range of important vaccines – proved

• Commercial advantages based on platform vectors

• Secure patent position – being expanded

• International industry validation & interest

• Regulatory & manufacturing progression occurring

• Commercial Strategy Implementation on track

==> picture [721 x 69] intentionally omitted <==